Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by WCM Investment Management LLC

WCM Investment Management LLC boosted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 191.4% in the first quarter, Holdings Channel reports. The fund owned 40,820,600 shares of the company’s stock after purchasing an additional 26,813,522 shares during the period. Teva Pharmaceutical Industries accounts for about 2.6% of WCM Investment Management LLC’s portfolio, making the stock its 13th biggest position. WCM Investment Management LLC’s holdings in Teva Pharmaceutical Industries were worth $1,157,264,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 2.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock valued at $1,384,216,000 after purchasing an additional 1,004,941 shares during the period. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 18.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 14.8% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock worth $1,167,323,000 after purchasing an additional 4,820,000 shares during the period. Norges Bank purchased a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $1,098,060,000. Finally, Rubric Capital Management LP grew its position in Teva Pharmaceutical Industries by 1.8% in the 2nd quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company’s stock valued at $435,760,000 after buying an additional 450,000 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the sale, the executive vice president directly owned 172,184 shares in the company, valued at $6,131,472.24. This trade represents a 47.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Christine Fox sold 21,258 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total value of $750,619.98. Following the sale, the executive vice president directly owned 63,647 shares in the company, valued at $2,247,375.57. The trade was a 25.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 465,931 shares of company stock worth $16,332,989. 0.54% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Trading Down 0.1%

Teva Pharmaceutical Industries stock opened at $32.00 on Monday. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The firm has a market capitalization of $36.79 billion, a price-to-earnings ratio of 24.06, a PEG ratio of 3.38 and a beta of 0.86. The firm has a 50-day moving average price of $33.76 and a two-hundred day moving average price of $32.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The company had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.99 earnings per share for the current year.

Analyst Ratings Changes

TEVA has been the subject of a number of analyst reports. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Friday. Piper Sandler restated an “overweight” rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Truist Financial lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, Barclays boosted their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.